Trupanion’s second quarter results were met with a positive market response, reflecting better-than-expected revenue growth and robust core business execution. Management identified an acceleration in pet enrollments, driven by enhancements to the customer enrollment experience and expanded deductible and coinsurance options. CEO Margi Tooth pointed to "improved web conversion" and "solid performance" from the company’s updated products as key contributors to net subscription pet growth, which rose 39% year over year. Early results from these initiatives also led to a 25% increase in the lifetime value of enrolled pets, supporting Trupanion’s ability to invest in further growth opportunities.

Is now the time to buy TRUP? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Trupanion’s Q2 Earnings Call

• Wilma Jackson Burdis (Raymond James): asked about ongoing veterinary inflation and its impact on pricing. CEO Margi Tooth said inflation remains elevated but is expected to normalize, and this is reflected in current pricing strategies.
• Wilma Jackson Burdis (Raymond James): inquired about the company’s use of its credit facility. CFO Fawwad Qureshi explained most of the revolver was drawn and highlighted ongoing debt reduction and strong interest income relative to expense.
• Joshua Shanker (Bank of America): questioned the rationale and timeline for the share repurchase program. Qureshi emphasized the company’s strong balance sheet and cash flows allow for both buybacks and internal investments, with prioritization based on expected returns.
• Joshua Shanker (Bank of America): sought detail on the relative returns of share repurchases versus pet acquisition investments. Qureshi replied decisions are made based on comparative returns, with flexibility to allocate capital dynamically.
• Brandon Vazquez (William Blair): asked about the timeline and impact of product changes on pet enrollments. Tooth stated the rollout is about halfway complete and early signs are encouraging, with full deployment expected by year-end.

Catalysts in Upcoming Quarters

In upcoming quarters, our analyst team will focus on (1) tracking the full North American rollout and adoption rates of expanded deductible and coinsurance options, (2) monitoring progress toward the planned digital insurance product launch and its initial uptake, and (3) evaluating the impact of further technology investments on operational efficiency and member experience. Additional attention will be given to trends in veterinary inflation and net pet additions as leading indicators of sustained growth.

Trupanion currently trades at $30.49, up from $24.39 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.